Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Research Council grant · Running

PolyAntiTumor Polyclonal anti-tumor immunity by engineered human T cells

Coordinator
Tel Aviv University, Israel
Runs
1 October 2022 to 30 September 2027
Status
Running
EU funding
€1.8m
Total cost
€1.8m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101042941

What the project is doing

In the project's own words, from its summary on CORDIS.

Adoptive T cell therapies are a new class of living drugs, achieving durable results in a subset of patients with aggressive malignancies. These transformative outcomes are not shared with the majority of patients with solid tumors that remain resistant to current T cell therapies. As engineered T cell therapy is usually directed against a single antigen, it is especially vulnerable to antigen loss as a tumor resistance mechanism.

Moreover, cancer immunotherapy often leads to severe immune-related adverse events (irAE) by destructive self-reactivity that must be evaluated together with the therapeutic benefit. While T cell therapies with tumor-infiltrating lymphocytes might circumvent these shortcomings, tumor tissue availability is limited and T cells are poorly responsive to ex-vivo perturbation. These therapeutic challenges highlight the gaps in our knowledge of how to engineer curative anti-tumor immunity.

We recently developed foundational platforms for CRISPR engineering, TCR repertoire manipulation, and single-cell omics of primary human T cells. We plan to leverage these opportune achievements to address the critical gaps in adoptive T cell therapies. We will focus on three important aspects of engineered anti-tumor immunity: efficacy, safety, and specificity. We will tune TCR sensitivity by perturbing key genes to determine how TCR signaling balances burst-like effector function and long-term persistence.

We will also reveal the sequestered self-reactive T cell compartment to control for irAE following immunotherapy. Finally, we will directly uncouple anti-tumor TCR repertoires from their dysfunctional state to mount a polyclonal anti-tumor immune response. This strategy is radically different from current T cell therapies as it is agnostic to specific tumor antigens and leverages pre-existing polyclonal antitumor immunity.

These studies will chart novel blueprints for robust, safe, and specific engineered cell therapies targeting solid tumors.

Topics

Who is involved

OrganisationCityCountryRole
Tel Aviv UniversityTel AvivIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI